Technical Analysis for EVLO - Evelo Biosciences, Inc.

Grade Last Price % Change Price Change
grade D 6.94 3.27% 0.22
EVLO closed up 3.27 percent on Wednesday, August 21, 2019, on 33 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical EVLO trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Overbought Strength 0.00%
Weak + Overbought Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.27%

Older signals for EVLO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:
Profile
Evelo Biosciences Inc operates as a bio-technology company. The firm develops therapies for the treatment of the gut-body network. Evelo Biosciences also offers treatment for cancer and inflammatory diseases.
Cancer Inflammatory Diseases Treatment For Cancer
Is EVLO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Aug 12 Evelo Biosciences (EVLO) CEO Simba Gill on Q2 2019 Results - Earnings Call Transcript
Aug 7 Evelo Biosciences, Inc. (EVLO) Q2 2019 Earnings Call Transcript
Aug 6 Insulet and Invacare among healthcare gainers; Endo International and InspireMD among losers
Aug 6 Early-stage data on Evelo's EDP1815 fails to excite investors, shares down 10%
Aug 6 Evelo Biosciences EPS misses by $0.01
Aug 6 Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial
Aug 6 Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results
Jul 30 Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, August 6th
Jul 25 Evelo Biosciences Secures $45 Million Debt Financing from K2 HealthVentures
Jul 15 Kaleido Biosciences Announces Appointment of Theo Melas-Kyriazi to its Board of Directors
See more EVLO news...
Indicators
Indicator Value
52 Week High 15.89
52 Week Low 4.8973
Average Volume 46,921
200-Day Moving Average 8.8146
50-Day Moving Average 7.334
20-Day Moving Average 6.2055
10-Day Moving Average 6.112
Average True Range 0.7268
ADX 19.48
+DI 22.5996
-DI 11.7538
Chandelier Exit (Long, 3 ATRs ) 5.7196
Chandelier Exit (Short, 3 ATRs ) 7.0777
Upper Bollinger Band 7.1569
Lower Bollinger Band 5.2541
Percent B (%b) 0.89
BandWidth 30.663121
MACD Line -0.2518
MACD Signal Line -0.4176
MACD Histogram 0.1658
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.24
Resistance 3 (R3) 7.24 7.15 7.19
Resistance 2 (R2) 7.15 7.07 7.15 7.17
Resistance 1 (R1) 7.04 7.02 7.10 7.04 7.16
Pivot Point 6.95 6.95 6.97 6.95 6.95
Support 1 (S1) 6.84 6.87 6.90 6.84 6.72
Support 2 (S2) 6.75 6.82 6.75 6.71
Support 3 (S3) 6.64 6.75 6.69
Support 4 (S4) 6.64